Market Place
Sourcing Support
Koselugo Shows Improve in NF1 Plexiform Neurofibromas in Ph 3 Trial
12 Nov 2024 //
BUSINESSWIRE
BIOTECanada Welcomes Three New Members to its Board of Directors
09 Oct 2024 //
BUSINESSWIRE
Alexion`s Biologic Soliris (Eculizumab) Receives Suppl Approval in US
19 Sep 2024 //
FDA
Alexion`s Biologic Ultomiris (Ravulizumab) Receives Suppl Approval in US
19 Sep 2024 //
FDA
Alexion Pharma`s Biologic Strensiq (asfotase alfa) Receives Approval in US
10 Jul 2024 //
FDA
Alexion Pharma`s Biologic Kanuma (sebelipase alfa) Receives Approval in US
10 Jul 2024 //
FDA
Alexion Pharma`s Biologic Soliris (exulizumab) Receives Approval in US
28 Jun 2024 //
FDA
Alexion`s Biologic Ultomiris (ravulizumab-cwvz) Receives Approvals in the US
28 Jun 2024 //
FDA
US FDA approves Amgen`s biosimilar to AZ`s rare blood disorder treatment
29 May 2024 //
REUTERS
Astrazeneca Amyloidosis Commitment: 2024 Isa Symposium Data Presented
23 May 2024 //
BUSINESSWIRE
Monte Rosa’s $100M offering; Alexion to hand back preclinical program to Zealand
16 May 2024 //
ENDPTS
AZ`s Alexion debuts short film highlighting NMOSD community
18 Apr 2024 //
FIERCE PHARMA
Lights, camera and community: AZ’s Alexion creates an original film
11 Apr 2024 //
FIERCE BIOTECH
Onco360 Has Selected as the Sole National Specialty Pharmacy Partner for Voydeya
08 Apr 2024 //
GLOBENEWSWIRE
Alexion Canada Appoints Karen Heim as New General Manager
02 Apr 2024 //
BIOSPACE
VOYDEYA™ Approved in The US & Ravulizumab or Eculizumab for the Rare Disease
01 Apr 2024 //
BUSINESSWIRE
FDA expands AZ`s Ultomiris to NMOSD after prior rejection
26 Mar 2024 //
FIERCE PHARMA
JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo
19 Mar 2024 //
BUSINESSWIRE
Alexion Pharma`s Biologic Soliris (eculizumab) Receives Approval in the U.S.
09 Feb 2024 //
FDA
Voyager asset lands on planet Alexion after Pfizer handoff
06 Nov 2023 //
FIERCE BIOTECH
Alexion data at Joint ECTRIMS-ACTRIMS Meeting showcase impact of C5 inhibition
11 Oct 2023 //
PRESS RELEASE
Alexion completes agreement for rare disease gene therapy portfolio from Pfizer
20 Sep 2023 //
PRESS RELEASE
SEC charges former Alexion VP Joseph Dupont with insider trading
30 Jun 2023 //
FIERCE PHARMA
Alexion touts early `proof-of-concept` data for Neurimmune antibody
22 May 2023 //
ENDPTS
Alexion advances commitment to transform outcomes in rare neurological diseases
02 Mar 2023 //
BUSINESSWIRE
NICE recommends Alexion’s asfotase alfa across England
27 Jan 2023 //
PHARMATIMES
AstraZeneca`s Alexion hopes to extend dominance in PNH
16 Dec 2022 //
FIERCEBIOTECH
ASH: Roche records rare disease win ahead of Soliris showdown
12 Dec 2022 //
FIERCEBIOTECH
Alexion, AZ Rare Disease, Completes Acquisition of LogicBio Therapeutics
16 Nov 2022 //
BUSINESSWIRE
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio
16 Nov 2022 //
BUSINESSWIRE
AZ expands global footprint in rare disease with availability of first Alexion
11 Nov 2022 //
PRESS RELEASE
JP Morgan splashes into the life sciences,tapping Stephen Squinto to run venture
01 Nov 2022 //
ENDPTS
Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS
12 Oct 2022 //
ASTRAZENECA-US
Alexion aims to advance NMOSD treatment landscape with ULTOMIRIS efficacy data
12 Oct 2022 //
BUSINESSWIRE
Alexion, AstraZeneca Rare Disease to Acquire LogicBio
04 Oct 2022 //
PRNEWSWIRE
EC approves Alexion’s Ultomiris for generalised myasthenia gravis
27 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
AstraZeneca`s Complementary PNH Treatment Hits the Mark in Phase III
17 Sep 2022 //
BIOSPACE
Argenx`s Vyvgart and Alexion`s Ultomiris Go Toe-to-Toe in Myasthenia Gravis
24 Aug 2022 //
PRNEWSWIRE
Xencor Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
On a roll, AstraZeneca flags looming approvals for three big drug franchises
26 Jul 2022 //
ENDPTS
Alexion puts €65M forward to strengthen its position on the Emerald Isle
27 Jun 2022 //
ENDPTS
AstraZeneca earmarks $68.7M for two Alexion plants in Ireland
24 Jun 2022 //
FIERCEPHARMA
UCB details positive pivotal data for myasthenia gravis
10 May 2022 //
ENDPTS
AstraZeneca Revenues up 56% in the Quarter.
09 May 2022 //
CONTRACTPHARMA
AstraZeneca Plans New R&D Center and Alexion Headquarters
02 May 2022 //
CONTRACTPHARMA
AZ`s rare disease rising star Ultomiris snags 3rd FDA nod
29 Apr 2022 //
FIERCEPHARMA
Alexion Pharmaceuticals`s Ravulizumab Receives Supplemental Approval in U.S.
27 Apr 2022 //
FDA
AstraZeneca`s Alexion, Arvinas nab space at new biotech tower
16 Apr 2022 //
FIERCEBIOTECH
AstraZeneca pays $775M to settle patent dispute over Alexion drug
18 Mar 2022 //
BIOPHARMADIVE
Roche, AstraZeneca settle Ultomiris patent lawsuit
19 Feb 2022 //
FIERCEPHARMA
Argenx`s Vyvgart is already winning neurologist support
17 Feb 2022 //
FIERCEPHARMA
Alexion and UK patient advocacy groups launch video campaign
16 Feb 2022 //
PHARMATIMES
Roche Unit, AstraZeneca’s Alexion Settle Ultomiris Patent Suit
16 Feb 2022 //
BLOOMBERGLAW
AZ`s R&D chiefs talk roxadustat, Imfinzi-treme
10 Feb 2022 //
FIERCEPHARMA
n-Lorem Receives $1M Donation From Alexion for Individualized Medicines
27 Jan 2022 //
BUSINESSWIRE
AstraZeneca picks up new weapon in fight with Alnylam and Pfizer
08 Jan 2022 //
CAMBRIDGEINDEPENDENT
AZ reportedly blocked buyout of rare disease specialist Sobi
03 Dec 2021 //
FIERCEPHARMA
